It is a modular urinalysis workflow launched by DIRUI, which can meet the realistic needs of clinical laboratories for automated and high-throughput urine testing.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Beckman Coulter Life Sciences announced on Monday that it has inked an application development agreement with Pillar Biosciences for next-generation sequencing solutions.

Gongdong Medical Technology announced that it plans to increase the capital of its wholly owned subsidiary GD Medical with its own funds or self-raised funds of 45 million US dollars to acquire the core assets of Trademark Plastics Inc. ("TPI").

BioMérieux announced on Wednesday that its third quarter revenues rose approximately 3 percent year over year due in part to unexpectedly strong sales in its BioFire product line.

DiaSorin reported Thursday its third quarter revenues declined 5 percent year over year with waning COVID-19 testing demand, despite rising revenues across its other diagnostics businesses.

On October 20, Sansure Biotech disclosed 2022 third quarter report, the company achieved revenue of CNY 4.068 billion in three quarters this year, an increase of 24.52% year-on-year; the net profit attributable to the mother achieved CNY 1.598 billion.

Danaher on Thursday reported a 6 percent year-over-year increase in third quarter revenues as its subsidiaries see shifting demand for COVID-19-related products, such as diagnostic tests and pharmaceuticals.

Avacta, a UK-based developer of cancer immunotherapies and diagnostics, said on Tuesday that it has signed an agreement to acquire Launch Diagnostics for up to ￡37 million ($41.9 million).

Pointe Biotech (Nanjing) Co., Ltd. (hereinafter referred to as: Pointe) and its shareholders formally reached a strategic consensus and completed the signing of the contract

The company raised its earnings forecast for 2022 on estimates of $7.8 billion in annual sales related to COVID-19 testing.

Roche’s third-quarter results have revealed a clear sign that the bumper sales boosting companies that have provided products to diagnose, treat or prevent COVID-19 since the start of the pandemic are starting to tail off.